International Journal of Radiation Oncology*Biology*Physics
Clinical InvestigationFactors Associated With the Development of Breast Cancer–Related Lymphedema After Whole-Breast Irradiation
Introduction
The incidence of breast cancer in the United States is approximately 200,000 cases per year, with up to 2.4 million women having a history of the disease (1). As outcomes continue to improve, so do the number of long-term survivors of breast cancer; therefore long-term toxicities affecting quality of life, such as breast cancer–related lymphedema (BCRL), are gaining greater importance.
Limited data exist on the risk of BCRL. On the basis of the therapeutic modalities used, rates reported using surgery, irradiation, and chemotherapy range from 5% with lumpectomy alone to up to 60% to 65% when treatment includes mastectomy with axillary lymph node dissection (ALND) and regional irradiation (2). Currently, up to 800,000 women have some form of BCRL based on incidence and prevalence rates of breast cancer and averaged rates of BCRL (2). Therefore analyses directed at identifying factors associated with its development and prevention are crucial.
Radiation therapy (RT) has been found to be a risk factor for the development of BCRL in multiple series, with a predominant focus on the role of regional irradiation 3, 4. Coen et al. (3) evaluated 727 patients who were treated with breast-conserving surgery and whole-breast irradiation (WBI) with or without the inclusion of regional lymphatics. The rate of BCRL at 10 years, defined as a difference in forearm circumference of greater than 2 cm, was 2% with tangents alone and 9% when regional nodal volumes were included, with axillary radiation as the only associated factor (3). In an evaluation of 2,579 women who received RT to the breast, the breast and supraclavicular region, or the breast, supraclavicular region, and posterior axillary boost, the rates of BCRL were 16%, 23%, and 31%, respectively. Risk factors identified included the addition of regional nodal irradiation, increasing weight, chemotherapy, and the number of nodes dissected (4). However, at this time, there are limited long-term data evaluating factors predictive of BCRL in patients undergoing RT.
The purpose of this analysis was to examine clinical, pathologic, and treatment factors associated with the development of BCRL after WBI and to identify high-risk patient groups who may benefit from aggressive interventions before the development of BCRL.
Section snippets
Methods and Materials
A total of 1,861 patients with breast cancer were treated at William Beaumont Hospital with WBI as part of their breast-conserving therapy from January 1980 to February 2006. Patients were prospectively entered into an institutional review board–approved database with pertinent patient, pathologic, treatment, and outcome data, including follow-up data, through September 2010. A total of 1,497 patients were available for analysis after the exclusion of patients with ductal carcinoma in situ,
Results
A total of 1,497 patients were available for evaluation. Patient characteristics for our study cohort are presented in Table 1. The majority of patients were white (92%), and only 29% of patients were under 50 years old. Nearly three-quarters of tumors were smaller than 2.0 cm, and 99% were 5.0 cm or less. Of note, three-quarters of patients had N0 disease; however, the mean and median number of axillary nodes sampled was 14 (range, 0–46). 24% received chemotherapy as neoadjuvant or adjuvant
Discussion
The results of this analysis show that the addition of regional irradiation (supraclavicular, posterior axillary, or internal mammary field) to WBI is not associated with a statistically significant increase in the incidence of BCRL. However, trends for increased rates were seen with the inclusion of supraclavicular and posterior axillary fields, suggesting that with increased numbers of patients examined, a relationship may exist. The true pathophysiology underlying BCRL is not fully
Conclusions
The results of this analysis show that nodal status, the number of nodes removed as part of an ALND, and administration of chemotherapy are associated with the development of BCRL. Regional irradiation appears to be associated with the development of BCRL based on previous series and the trends seen in this analysis. High-risk subgroups of patients can be identified and may potentially benefit from prophylactic treatment and surveillance with new diagnostic modalities.
References (18)
- et al.
Self-reported arm-lymphedema and functional impairment after breast cancer treatment—A nationwide study of prevalence and associated factors
The Breast
(2010) - et al.
Does axillary boost increase lymphedema compared with supraclavicular alone after breast conservation?
Int J Radiat Oncol Biol Phys
(2008) - et al.
The incidence of arm edema in women with breast cancer randomized on the National Surgical Adjuvant Breast and Bowel Project Study B-04 to radical mastectomy versus total mastectomy and radiotherapy versus total mastectomy alone
Int J Radiat Oncol Biol Phys
(2008) - et al.
Cancer statistics, 2007
CA Cancer J Clin
(2007) - et al.
Risk of lymphedema after regional nodal irradiation with breast conservation therapy
Int J Radiat Oncol Biol Phys
(2003) - et al.
Tumors induce complex DNA damage in distant proliferative tissues in vivo
Proc Natl Acad Sci U S A
(2010) - et al.
Bisphosphonate effects in cancer and inflammatory diseases: In vitro and in vivo modulation of cytokine activities
BioDrugs
(2004) - et al.
Risk factors for lymphedema in breast cancer survivors, the Iowa Women’s Health Study
Breast Cancer Res Treat
(2011 Jun 15) - et al.
Morbidity results from the NSABP-32 trial comparing sentinel lymph node dissection versus axillary dissection
J Surg Oncol
(2010)
Cited by (48)
Risk factors for lower extremity lymphedema after inguinal lymphadenectomy in melanoma patients: A retrospective cohort study
2022, Surgery Open ScienceCitation Excerpt :All in all, the number of LNs removed ≥ 10 was found to be significantly associated with the development of lymphedema. Studies have shown that the number of dissected axillary lymph nodes was the risk factor for breast cancer–related lymphedema [31,32]. One explanation may be that having more LNs removed resulted in broader incisions to dissect LNs.
Timing of Lymphedema After Treatment for Breast Cancer: When Are Patients Most At Risk?
2019, International Journal of Radiation Oncology Biology PhysicsTrends and Patterns of Utilization of Hypofractionated Postmastectomy Radiotherapy: A National Cancer Database Analysis
2018, Clinical Breast CancerCitation Excerpt :Our results also show that the overall use of hypofractionation was selective, likely reflecting a lack of clarity regarding optimal patient selection. The decreased likelihood of treating patients with node-positive disease with hypofractionation might reflect a concern that treating the regional lymph nodes with hypofractionation might increase the risk of lymphedema.36 Our findings also suggest a reluctance to use hypofractionated PMRT in the setting of a breast reconstruction and previous chemotherapy use, both of which are settings in which further research is warranted to allay concerns regarding acute as well as chronic side effects.
Management of the Regional Lymph Nodes in Early-Stage Breast Cancer
2016, Seminars in Radiation Oncology
Conflict of interest: none.